NBIX

182.83

3.64% 6.42

Handel nachbörslich: 183.01 0.18 +0.10%

Neurocrine Biosciences Inc (NBIX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$176.41

Offen:

$178.84

24-Stunden-Volumen:

1.33M

Relative Volume:

1.12

Marktkapitalisierung:

$18.38B

Einnahmen:

$3.10B

Nettoeinkommen (Verlust:

$668.60M

KGV:

28.11

EPS:

6.5044

Netto-Cashflow:

$831.30M

1W Leistung:

+2.11%

1M Leistung:

+8.49%

6M Leistung:

+35.77%

1J Leistung:

+36.74%

1-Tages-Spanne:

$176.25

$182.91

1-Wochen-Bereich:

$170.00

$182.91

52-Wochen-Spanne:

$122.14

$182.91

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Firmenname

Neurocrine Biosciences Inc

Sektor

Healthcare (1076)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

(858) 617-7600

Adresse

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Mitarbeiter

2,000

Twitter

Nächster Verdiensttermin

2026-07-30

Neueste SEC-Einreichungen

NBIX's Discussions on Twitter

Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NBIX Neurocrine Biosciences Inc	182.83	17.74B	3.10B	668.60M	831.30M	6.5044
TAK Takeda Pharmaceutical Co Adr	17.52	55.69B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.27	43.77B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.67	36.19B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	77.51	32.25B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	523.63	26.29B	3.17B	1.29B	1.01B	27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2026-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-10-21	Eingeleitet	Citigroup	Buy
2025-07-21	Eingeleitet	Truist	Buy
2025-07-10	Eingeleitet	Goldman	Buy
2025-04-15	Hochstufung	Needham	Hold → Buy
2025-04-14	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Eingeleitet	Deutsche Bank	Hold
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-08-29	Hochstufung	Piper Sandler	Neutral → Overweight
2024-04-24	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-12-13	Fortgesetzt	Citigroup	Neutral
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-10-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2023-08-21	Bestätigt	Mizuho	Neutral
2023-07-24	Hochstufung	SVB Securities	Market Perform → Outperform
2023-07-06	Hochstufung	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Hochstufung	Guggenheim	Neutral → Buy
2023-03-30	Hochstufung	Canaccord Genuity	Hold → Buy
2023-03-03	Hochstufung	Evercore ISI	In-line → Outperform
2023-02-03	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Herabstufung	Evercore ISI	Outperform → In-line
2022-10-11	Eingeleitet	UBS	Buy
2022-09-26	Eingeleitet	Wells Fargo	Equal Weight
2022-06-06	Fortgesetzt	Jefferies	Buy
2022-03-03	Herabstufung	Piper Sandler	Overweight → Neutral
2022-02-25	Hochstufung	Goldman	Neutral → Buy
2022-01-18	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Eingeleitet	BMO Capital Markets	Underperform
2021-11-17	Hochstufung	JP Morgan	Neutral → Overweight
2021-10-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Fortgesetzt	Needham	Hold
2021-08-06	Herabstufung	Canaccord Genuity	Buy → Hold
2021-05-18	Fortgesetzt	Goldman	Neutral
2021-05-06	Hochstufung	Barclays	Equal Weight → Overweight
2021-02-02	Eingeleitet	Raymond James	Outperform
2020-09-30	Eingeleitet	The Benchmark Company	Hold
2020-08-04	Herabstufung	JP Morgan	Overweight → Neutral
2020-06-29	Herabstufung	Goldman	Buy → Neutral
2020-06-09	Eingeleitet	Wedbush	Outperform
2020-03-06	Eingeleitet	Citigroup	Buy
2020-02-27	Eingeleitet	Barclays	Equal Weight
2020-02-24	Eingeleitet	William Blair	Outperform
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-02-05	Bestätigt	H.C. Wainwright	Buy
2019-12-13	Herabstufung	Credit Suisse	Outperform → Neutral
2019-08-07	Eingeleitet	RBC Capital Mkts	Outperform
2019-07-16	Eingeleitet	Oppenheimer	Outperform
2019-06-05	Eingeleitet	Guggenheim	Neutral
2019-05-21	Eingeleitet	Credit Suisse	Outperform
2019-04-22	Hochstufung	JP Morgan	Neutral → Overweight
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-02-06	Bestätigt	BofA/Merrill	Buy
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-12-13	Eingeleitet	Goldman	Buy
2018-11-21	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten

11:56 AM

Neurocrine Biosciences stock hits all-time high at 181.3 USD - Investing.com

11:56 AM

Jul 27, 2026

NBIX|Neurocrine Biosciences Inc|Price:176.825|Chg%:+1.055 - TradingKey

Jul 27, 2026

Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – HAM:NB3 - TradingView

Jul 27, 2026

Weekly Recap: Guggenheim hikes NBIX price target and Siddhanti named CBO - TradingView

Jul 27, 2026

Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup - ChartMill

Jul 27, 2026

Jul 26, 2026

SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits

Jul 26, 2026

Neurocrine Biosciences (NBIX) Refreshes Leadership On A Narrative That Still Sees Undervaluation - simplywall.st

Jul 26, 2026

Jul 25, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock - ChartMill

Jul 25, 2026

Jul 24, 2026

How Investors Are Reacting To Neurocrine Biosciences (NBIX) Leadership Hires In Business And Market Access - simplywall.st

Jul 24, 2026

Neurocrine Biosciences Names New Senior Vice Presidents - Contract Pharma

Jul 24, 2026